Cost-effectiveness analyses and indirect treatment comparisons are important areas of health economics and outcomes research and when conducting these analyses, individual patient data (IPD) can provide valuable insight. Often, however,…
With 2021 having drawn to a close, we thought we would take the opportunity to look back on what has been another successful year for Broadstreet. Of course, the pandemic…
As another busy and productive year draws to a close here at Broadstreet, we wanted to take a few minutes to wish our friends, clients and colleagues a safe and…
Early clinical successes are becoming more common in oncology; and as a result, there is a need for endpoints that can meaningfully describe outcomes among treated patients. In cases where…
Broadstreet is pleased to be presenting several posters at this year’s virtual ISPOR Europe meeting. USE OF REAL-WORLD EVIDENCE TO EVALUATE INFLIXIMAB BIOSIMILARS: A SCOPING REVIEW Antoinette Cheung,1 Lauren Powell,1…
Broadstreet is pleased to be contributing to a greater understanding of the contemporary burden of Duchenne muscular dystrophy (DMD) with this new publication in the Journal of Managed Care and…
Broadstreet, collaborating with Bonnie Donato (Boehringer Ingelheim), has been looking at how high deductible health plans affect access to care in the US. Ahead of our upcoming journal publication on…
Our collaborative work with the Biohaven team on migraine continues to reveal new insights about the condition and we are pleased to have had some of our most recent research…
We’re very excited to announce the launch of our new website, a beautifully designed digital home that reflects who we are, what we do and how we’ve evolved over the…
Because we are epidemiologists, we often have people asking us questions about COVID-19 in general and about the vaccines in particular. Like many others, we have been awed and grateful…